Two stocks in Healthcare
Eurofins Scientific vs Gerresheimer: profit, growth, debt and price compared
Eurofins Scientific is stronger on 4 of 6 figures: profit margin, sales growth, debt and price trend. Gerresheimer is stronger on 1: price for its expected profit.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Eurofins ScientificERF.PA | GerresheimerGXI.DE | |
|---|---|---|
| Net margin | Stronger: 7.2% | −17.5% |
| Revenue growth, past year | Stronger: +2.50% | −0.80% |
| Debt to equity | Stronger: 96.1% | 236.7% |
| Forward P/E | 17.9× | Stronger: 13.5× |
| Dividend yield | 0.82% | — |
| Analysts | Hold · 14 | Hold · 12 |
| From its 200-day average | Stronger: +18.5% | +13.7% |
Share price over the past year
- Eurofins Scientific+45.4%
- Gerresheimer+36.7%
24 Nov 202518 Nov 2026
Eurofins Scientific or Gerresheimer: which is stronger?
- ERF.PA
Which is more profitable?
Eurofins Scientific keeps more of each sale as profit: 7.2% against −17.5%.
- ERF.PA
Which is growing its sales faster?
Eurofins Scientific is growing its sales faster: +2.50% over the past year, against −0.80%.
- ERF.PA
Which has borrowed less?
Eurofins Scientific has borrowed less: its debt is 96.1% of what its shareholders own, against 236.7% for Gerresheimer.
- GXI.DE
Which costs less for the profit it is expected to make?
Gerresheimer costs less for the profit it is expected to make: 13.5× its forward earnings, against 17.9×.
Which pays more in dividends?
Eurofins Scientific pays 0.82% a year in dividends for what a share costs, where Gerresheimer pays none.
Which do analysts rate higher?
Analysts rate both the same: Hold.
- ERF.PA
Which is in the stronger price trend?
Eurofins Scientific's price is in the stronger trend: 18.5% above its 200-day average, against 13.7% above.
What each company does
ERF.PAEurofins Scientific
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide.
Reports results on 28 January 2027
GXI.DEGerresheimer
Gerresheimer AG, together with its subsidiaries, provides drug containment solutions in Germany and internationally.
Reports results on 25 November 2026
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.